Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis

Recruiting now · Phase 2

Conditions studied: Neurotrophic Keratitis

In brief

The objective of this study is to obtain initial efficacy of BRM424 in patients with Stage 2 and Stage 3 NK and evaluate safety and tolerability.

Key facts

Study ID

NCT05927428

Run by

BRIM Biotechnology Inc.

People needed

12

Starts

2024-07-31

Expected to finish

2025-11-30

Last updated by the study team

2024-10-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Be at least 18 years of age;
• Provide written informed consent;
• Patients with NK Stage 2 (PED) or Stage 3 (corneal ulcer);

You may not qualify if…

• Any active ocular infection (bacterial, viral, fungal or protozoal) or active ocular inflammation not related to NK;
• Anticipated need to use therapeutic contact lenses or contact lens wear for refractive correction during the 28-days Treatment Period in the eye(s) with NK;
• Be a woman of childbearing potential who is not using an acceptable means of birth control;

Where it is running

• Wilmington Eye — Leland, North Carolina, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.